AR088327A1 - Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes - Google Patents
Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunesInfo
- Publication number
- AR088327A1 AR088327A1 ARP120103811A ARP120103811A AR088327A1 AR 088327 A1 AR088327 A1 AR 088327A1 AR P120103811 A ARP120103811 A AR P120103811A AR P120103811 A ARP120103811 A AR P120103811A AR 088327 A1 AR088327 A1 AR 088327A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- nhc
- cr6r7
- independently selected
- alkynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos que inhiben la actividad de las proteínas antiapoptóticas Bcl-xL, composiciones que contienen dichos compuestos y métodos para tratar enfermedades en las que se expresan las proteínas antiapoptóticas Bcl-xL. Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1) o una sal aceptable para terapia del mismo, donde X es heteroarilo; donde el heteroarilo representado por X está opcionalmente sustituido con uno, dos, tres, o cuatro R⁴; Y¹ es fenileno o heteroarileno C₅₋₆; opcionalmente fusionado a uno o dos anillos seleccionados entre el grupo que consiste en cicloalcano C₃₋₈, cicloalqueno C₃₋₈, benceno, heteroareno C₅₋₆, heterocicloalcano C₃₋₈, y heterocicloalqueno C₃₋₈; donde Y¹ está opcionalmente sustituido con uno, dos, tres, o cuatro sustituyentes seleccionados en forma independiente entre el grupo que consiste en R⁵, OR⁵, SR⁵, S(O)R⁵, SO₂R⁵, C(O)R⁵, CO(O)R⁵, OC(O)R⁵, OC(O)OR⁵, NH₂, NHR⁵, N(R⁵)₂, NHC(O)R⁵, NR⁵C(O)R⁵, NHS(O)₂R⁵, NR⁵S(O)₂R⁵, NHC(O)OR⁵, NR⁵C(O)OR⁵, NHC(O)NH₂, NHC(O)NHR⁵, NHC(O)N(R⁵)₂, NR⁵C(O)NHR⁵, NR⁵C(O)N(R⁵)₂, C(O)NH₂, C(O)NHR⁵, C(O)N(R⁵)₂, C(O)NHOH, C(O)NHOR⁵, C(O)NHSO₂R⁵, C(O)NR⁵SO₂R⁵, SO₂NH₂, SO₂NHR⁵, SO₂N(R⁵)₂, CO(O)H, C(O)H, OH, CN, N₅, NO₂, F, Cl, Br y I; L¹ se selecciona entre el grupo que consiste en (CR⁶R⁷)q, (CR⁶R⁷)ₛ-O-(CR⁶R⁷)ʳ, (CR⁶R⁷)ₛ-C-(O)-(CR⁶R⁷)ʳ, (CR⁶R⁷)ₛ-S-(CR⁶R⁷)ʳ, (CR⁶R⁷)ₛ-S(O)₂-(CR⁶R⁷)ʳ, (CR⁶R⁷)ₛ-NR⁶AC(O)-(CR⁶R⁷)ʳ, (CR⁶R⁷)ₛ-C(O)NR⁶A-(CR⁶R⁷)ʳ, (CR⁶R⁷)ₛ-NR⁶A-(CR⁶R⁷)ʳ, (CR⁶R⁷)ₛ-S(O)₂NR⁶A-(CR⁶R⁷)ʳ, y (CR⁶R⁷)ₛ-NR⁶AS(O)₂-(CR⁶R⁷)ʳ; Y² es cicloalquilo C₈₋₁₄, cicloalquenilo C₈₋₁₄, heterocicloalquilo C₈₋₁₄, o heterocicloalquenilo C₈₋₁₄; opcionalmente fusionado a uno o dos anillos seleccionados entre el grupo que consiste en cicloalcano C₃₋₈, cicloalqueno C₃₋₈, benceno, heteroareno C₅₋₆, heterocicloalcano C₃₋₈, y heterocicloalqueno C₃₋₈; donde Y² está opcionalmente sustituido con uno, dos, tres, cuatro, o cinco sustituyentes seleccionados en forma independiente entre el grupo que consiste en R⁸, OR⁸, SR⁸, S(O)R⁸, SO₂R⁸, C(O)R⁸, CO(O)R⁸, OC(O)R⁸, OC(O)OR⁸, NH₂, NHR⁸, N(R⁸)₂, NHC(O)R⁸, NR⁸C(O)R⁸, NHS(O)₂R⁸, NR⁸S(O)₂R⁸, NHC(O)OR⁸, NR⁸C(O)OR⁸, NHC(O)NH₂, NHC(O)NHR⁸, NHC(O)N(R⁸)₂, NR⁸C(O)NHR⁸, NR⁸C(O)N(R⁸)₂, C(O)NH₂, C(O)NHR⁸, C(O)N(R⁸)₂, C(O)NHOH, C(O)NHOR⁸, C(O)NHSO₂R⁸, C(O)NR⁸SO₂R⁸, SO₂NH₂, SO₂NHR⁸, SO₂N(R⁸)₂, CO(O)H, C(O)H, OH, CN, N₃, NO₂, F, Cl, Br y I; Z¹ se selecciona entre el grupo que consiste en C(O)OR⁹, C(O)NR¹⁰R¹¹, C(O)R¹¹, NR¹⁰C(O)R¹¹, NR¹⁰C(O)NR¹⁰R¹¹, OC(O)NR¹⁰R¹¹, NR¹⁰C(O)OR⁹, C(=NOR¹⁰)NR¹⁰R¹¹, NR¹⁰C(=NCN)NR¹⁰R¹¹, NR¹⁰S(O)₂NR¹⁰R¹¹, S(O)₂R⁹, S(O)₂NR¹⁰R¹¹, N(R¹⁰)S(O)₂R¹¹, NR¹⁰C(=NR¹¹)NR¹⁰R¹¹, C(=S)NR¹⁰R¹¹, C(=NR¹⁰)NR¹⁰R¹¹, halógeno, NO₂, y CN; o Z¹ se selecciona entre el grupo que consiste en el grupo de formulas (2); R¹, en cada caso, se selecciona en forma independiente entre el grupo que consiste en halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, y haloalquilo C₁₋₆; R², en cada caso, se selecciona en forma independiente entre el grupo que consiste en deuterio, halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, y haloalquilo C₁₋₆; dos R² que se unen al mismo átomo de carbono, junto con dicho átomo de carbono, forman opcionalmente un anillo seleccionado entre el grupo que consiste en heterocicloalquilo, heterocicloalquenilo, cicloalquilo, y cicloalquenilo; R³, en cada caso, se selecciona en forma independiente entre el grupo que consiste en halo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, y haloalquilo C₁₋₆; R⁴, en cada caso, se selecciona en forma independiente entre el grupo que consiste en NR¹²R¹³, OR¹², CN, NO₂, halógeno, C(O)OR¹², C(O)NR¹²R¹³, NR¹²C(O)R¹³, NR¹²S(O)₂R¹⁴, NR¹²S(O)R¹⁴, S(O)₂R¹⁴, S(O)R¹⁴ y R¹⁴; R⁵, en cada caso, se selecciona en forma independiente entre el grupo que consiste en alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, arilo, heterociclilo, cicloalquilo, y cicloalquenilo; R⁶A se selecciona en forma independiente entre el grupo que consiste en hidrógeno, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, y haloalquilo C₁₋₆; R⁶ y R⁷, en cada caso, se seleccionan en forma independiente entre sí entre el grupo que consiste en hidrógeno, R¹⁵, OR¹⁵, SR¹⁵, S(O)R¹⁵, SO₂R¹⁵, C(O)R¹⁵, CO(O)R¹⁵, OC(O)R¹⁵, OC(O)OR¹⁵, NH₂, NHR¹⁵, N(R¹⁵)₂, NHC(O)R¹⁵, NR¹⁵C(O)R¹⁵, NHS(O)₂R¹⁵, NR¹⁵S(O)₂R¹⁵, NHC(O)OR¹⁵, NR¹⁵C(O)OR¹⁵, NHC(O)NH₂, NHC(O)NHR¹⁵, NHC(O)N(R¹⁵)₂, NR¹⁵C(O)NHR¹⁵, NR¹⁵C(O)N(R¹⁵)₂, C(O)NH₂, C(O)NHR¹⁵, C(O)N(R¹⁵)₂, C(O)NHOH, C(O)NHOR¹⁵, C(O)NHSO₂R¹⁵, C(O)NR¹⁵SO₂R¹⁵, SO₂NH₂, SO₂NHR¹⁵, SO₂N(R¹⁵)₂, CO(O)H, C(O)H, OH, CN, N₃, NO₂, F, Cl, Br y I; R⁸, en cada caso, se selecciona en forma independiente entre el grupo que consiste en alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, arilo, heterociclilo, cicloalquilo, y cicloalquenilo; donde R⁸ alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, y haloalquilo C₁₋₆ están opcionalmente sustituidos con uno, dos, tres, cuatro, cinco, o seis sustituyentes seleccionados en forma independiente entre el grupo que consiste en R¹⁶, OR¹⁶, SR¹⁶, S(O)R¹⁶, SO₂R¹⁶, C(O)R¹⁶, CO(O)R¹⁶, OC(O)R¹⁶, OC(O)OR¹⁶, NH₂, NHR¹⁶, N(R¹⁶)₂, NHC(O)R¹⁶, NR¹⁶C(O)R¹⁶, NHS(O)₂R¹⁶, NR¹⁶S(O)₂R¹⁶, NHC(O)OR¹⁶, NR¹⁶C(O)OR¹⁶, NHC(O)NH₂, NHC(O)NHR¹⁶, NHC(O)N(R¹⁶)₂, NR¹⁶C(O)NHR¹⁶, NR¹⁶C(O)N(R¹⁶)₂, C(O)NH₂, C(O)NHR¹⁶, C(O)N(R¹⁶)₂, C(O)NHOH, C(O)NHOR¹⁶, C(O)NHSO₂R¹⁶, C(O)NR¹⁶SO₂R¹⁶, SO₂NH₂, SO₂NHR¹⁶, SO₂N(R¹⁶)₂, CO(O)H, C(O)H, OH, CN, N₃, NO₂, F, Cl, Br y I; donde R⁸ arilo, heterociclilo, cicloalquilo, y cicloalquenilo están opcionalmente sustituidos con uno, dos o tres sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, NH₂, C(O)NH₂, SO₂NH₂, C(O)H, (O), OH, CN, NO₂, OCF₃, OCF₂CF₃, F, Cl, Br y I; R⁹ se selecciona entre el grupo que consiste en alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, haloalquilo C₁₋₆, cicloalquilo, fenilo y (CH₂)₁₋₄-fenilo; y R¹⁰ y R¹¹, en cada caso, se seleccionan en forma independiente entre sí entre el grupo que consiste en hidrógeno, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆, haloalquilo C₁₋₆, fenilo y (CH₂)₁₋₄-fenilo; o R¹⁰ y R¹¹, o R¹⁰ y R⁹, junto con el átomo al cual están unidos se combinan para formar un heterociclilo; Rᵏ, en cada caso, se selecciona en forma independiente entre el grupo que consiste en alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋Ȉ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547162P | 2011-10-14 | 2011-10-14 | |
CN2012079012 | 2012-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR088327A1 true AR088327A1 (es) | 2014-05-28 |
Family
ID=47116421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120103811A AR088327A1 (es) | 2011-10-14 | 2012-10-12 | Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes |
Country Status (36)
Country | Link |
---|---|
EP (1) | EP2766361B1 (es) |
JP (2) | JP6155270B2 (es) |
KR (1) | KR102019643B1 (es) |
AR (1) | AR088327A1 (es) |
AU (2) | AU2012322698A1 (es) |
BR (1) | BR112014009053B1 (es) |
CA (1) | CA2851364C (es) |
CL (1) | CL2014000905A1 (es) |
CO (1) | CO6950476A2 (es) |
CR (2) | CR20200097A (es) |
CY (1) | CY1118224T1 (es) |
DK (1) | DK2766361T3 (es) |
DO (2) | DOP2014000070A (es) |
EC (1) | ECSP14000357A (es) |
ES (1) | ES2598877T3 (es) |
GT (1) | GT201400064A (es) |
HK (1) | HK1200167A1 (es) |
HR (1) | HRP20161319T1 (es) |
HU (1) | HUE030589T2 (es) |
IL (1) | IL231856A (es) |
LT (1) | LT2766361T (es) |
ME (1) | ME02514B (es) |
MX (1) | MX356031B (es) |
PE (1) | PE20141282A1 (es) |
PH (1) | PH12015501498A1 (es) |
PL (1) | PL2766361T3 (es) |
PT (1) | PT2766361T (es) |
RS (1) | RS55342B1 (es) |
RU (1) | RU2625315C2 (es) |
SG (1) | SG11201401279XA (es) |
SI (1) | SI2766361T1 (es) |
TW (1) | TWI571466B (es) |
UA (1) | UA115042C2 (es) |
UY (1) | UY34382A (es) |
WO (1) | WO2013055897A1 (es) |
ZA (1) | ZA201402556B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI561521B (en) | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
EP3229844B1 (en) * | 2014-12-09 | 2020-03-04 | AbbVie Inc. | Antibody drug conjugates with cell permeable bcl-xl inhibitors |
MX2017007629A (es) * | 2014-12-09 | 2018-05-17 | Abbvie Inc | Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen. |
MX2017007637A (es) * | 2014-12-09 | 2017-09-05 | Abbvie Inc | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. |
CN104473923B (zh) * | 2014-12-29 | 2016-08-17 | 巩春智 | 一种防治慢性心力衰竭的药物组合物及其应用 |
WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
CN116059201A (zh) * | 2016-06-08 | 2023-05-05 | 艾伯维公司 | 抗egfr抗体药物偶联物 |
MX2018015280A (es) * | 2016-06-08 | 2019-08-12 | Abbvie Inc | Conjugados de anticuerpo y farmaco anti-egfr. |
JP2019524649A (ja) * | 2016-06-08 | 2019-09-05 | アッヴィ・インコーポレイテッド | 抗cd98抗体及び抗体薬物コンジュゲート |
CN109562169A (zh) * | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
CN116284404A (zh) | 2016-06-08 | 2023-06-23 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
MX2018015272A (es) * | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
EP3468615A1 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
WO2018092064A1 (en) * | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
WO2019000236A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
WO2019178433A1 (en) | 2018-03-15 | 2019-09-19 | Abbvie Inc. | Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer |
AR119494A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS |
JP2023553811A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Bcl-xl阻害剤抗体-薬物コンジュゲートおよびその使用方法 |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
CA3206906A1 (en) | 2021-02-02 | 2022-08-11 | Andras Herner | Selective bcl-xl protac compounds and methods of use |
WO2023215449A1 (en) * | 2022-05-06 | 2023-11-09 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
WO2023215482A1 (en) * | 2022-05-06 | 2023-11-09 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
WO2023236814A1 (zh) * | 2022-06-10 | 2023-12-14 | 成都先导药物开发股份有限公司 | 一种化合物及其在制备bcl-xl抑制剂中的用途 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
JPH11512429A (ja) | 1995-09-15 | 1999-10-26 | ファルマシア・アンド・アップジョン・カンパニー | アミノアリールオキサゾリジノン n−オキシド |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
IL153278A0 (en) * | 2000-06-21 | 2003-07-06 | Hoffmann La Roche | Benzothiazole derivatives |
CA2508947A1 (en) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
BRPI0810362A2 (pt) | 2007-04-19 | 2014-10-29 | Concert Pharmaceuticals Inc | Compostos de morfolinila deuterados |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
NZ593536A (en) * | 2008-12-19 | 2013-07-26 | Genentech Inc | Quinoline derivatives and methods of use |
RU2525116C2 (ru) * | 2008-12-19 | 2014-08-10 | Дженентек, Инк. | Гетероциклические соединения и способы применения |
KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2012
- 2012-10-08 TW TW101137131A patent/TWI571466B/zh active
- 2012-10-10 UY UY0001034382A patent/UY34382A/es unknown
- 2012-10-11 HU HUE12780605A patent/HUE030589T2/en unknown
- 2012-10-11 RU RU2014119250A patent/RU2625315C2/ru active
- 2012-10-11 DK DK12780605.7T patent/DK2766361T3/en active
- 2012-10-11 ES ES12780605.7T patent/ES2598877T3/es active Active
- 2012-10-11 PL PL12780605T patent/PL2766361T3/pl unknown
- 2012-10-11 BR BR112014009053-0A patent/BR112014009053B1/pt active IP Right Grant
- 2012-10-11 PT PT127806057T patent/PT2766361T/pt unknown
- 2012-10-11 WO PCT/US2012/059720 patent/WO2013055897A1/en active Application Filing
- 2012-10-11 ME MEP-2016-227A patent/ME02514B/me unknown
- 2012-10-11 KR KR1020147012846A patent/KR102019643B1/ko active IP Right Grant
- 2012-10-11 AU AU2012322698A patent/AU2012322698A1/en not_active Abandoned
- 2012-10-11 MX MX2014004556A patent/MX356031B/es active IP Right Grant
- 2012-10-11 EP EP12780605.7A patent/EP2766361B1/en active Active
- 2012-10-11 RS RS20160954A patent/RS55342B1/sr unknown
- 2012-10-11 SG SG11201401279XA patent/SG11201401279XA/en unknown
- 2012-10-11 PE PE2014000506A patent/PE20141282A1/es active IP Right Grant
- 2012-10-11 JP JP2014535869A patent/JP6155270B2/ja active Active
- 2012-10-11 SI SI201230730A patent/SI2766361T1/sl unknown
- 2012-10-11 CA CA2851364A patent/CA2851364C/en active Active
- 2012-10-11 CR CR20200097A patent/CR20200097A/es unknown
- 2012-10-11 UA UAA201405089A patent/UA115042C2/uk unknown
- 2012-10-11 LT LTEP12780605.7T patent/LT2766361T/lt unknown
- 2012-10-12 AR ARP120103811A patent/AR088327A1/es active IP Right Grant
-
2014
- 2014-04-01 IL IL231856A patent/IL231856A/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02556A patent/ZA201402556B/en unknown
- 2014-04-09 DO DO2014000070A patent/DOP2014000070A/es unknown
- 2014-04-10 GT GT201400064A patent/GT201400064A/es unknown
- 2014-04-10 CL CL2014000905A patent/CL2014000905A1/es unknown
- 2014-05-06 CR CR20140205A patent/CR20140205A/es unknown
- 2014-05-07 CO CO14097093A patent/CO6950476A2/es unknown
- 2014-05-08 EC ECIEPI2014357A patent/ECSP14000357A/es unknown
-
2015
- 2015-01-16 HK HK15100555.0A patent/HK1200167A1/zh unknown
- 2015-06-30 PH PH12015501498A patent/PH12015501498A1/en unknown
-
2016
- 2016-10-11 HR HRP20161319TT patent/HRP20161319T1/hr unknown
- 2016-10-27 CY CY20161101096T patent/CY1118224T1/el unknown
-
2017
- 2017-04-19 JP JP2017082912A patent/JP6395893B2/ja active Active
- 2017-07-20 AU AU2017206246A patent/AU2017206246B2/en active Active
-
2019
- 2019-02-01 DO DO2019000022A patent/DOP2019000022A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR124117A2 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes | |
AR088327A1 (es) | Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes | |
AR088328A1 (es) | Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes | |
AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
AR107488A1 (es) | Compuestos de benzopirazol y análogos de éstos | |
AR096748A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
AR095326A1 (es) | Heterociclos tricíclicos como inhibidores de la proteína bet | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
AR108011A1 (es) | Moduladores receptores de estrógenos | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR095609A1 (es) | Compuestos de pirrolopiridina | |
AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
AR097325A1 (es) | Pirroles anillados | |
AR101528A1 (es) | Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
AR099047A1 (es) | Derivados etinilo | |
AR093057A1 (es) | Inhibidores de la syk | |
AR099828A1 (es) | Uso de oxotetrahidroquinolinilsulfonamidas sustituidas o sus sales para aumentar la tolerancia al estrés en plantas | |
AR101479A1 (es) | Derivados de 6-alquinil-piridina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |